Myeloma Paper of the Day, August 9th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Modeling study of SEER data finds non-Hispanic Black population had a higher Monoclonal Gammopathy of Undetermined Significance (MGUS) incidence rate at all ages and a shorter pre-clinical duration of myeloma versus non-Hispanic White counterparts.”
Source: Robert Orlowski/X
Authors: Mengmeng Ji, Yi-Hsuan Shih, John H. Huber, Mei Wang, Eric J. Feuer, Ruth Etzioni, Shi-Yi Wang and Su-Hsin Chang.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
